Stifel cuts Stryker stock price target on weak quarter, guidance
Stifel reduced its price target for Stryker (NYSE:SYK) to $325 from $330, maintaining a Buy rating after the company's Q3 results missed expectations. Stryker reported Q3 sales of $6.52B, below estimates, and lowered its full-year organic sales growth guidance to 6.5-7.0%. Multiple analysts have revised earnings downward, citing execution issues and market slowdowns.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut are likely to trigger a sell‑off, especially given the lowered price targets from several sell‑side houses.
Market read
Primary earnings and guidance news for a large‑cap med‑device company, with immediate price target revisions.
What to watch
Supply chain issues and cyber‑attack pressures may be temporary, and the orthopedics segment still posted growth.
Background
Stryker reported Q3 2026 sales of $6.52B, missing estimates, and cut organic growth guidance to 6.5‑7.0%. Multiple analysts trimmed price targets.
Ticker impact
Stifel lowered SYK price target to $325 and Stryker cut full-year organic sales guidance after Q3 miss.
likely downside pressure as the market prices in the guidance cut and lower target.
Earnings miss and guidance reduction are fresh primary facts for a large‑cap med‑device maker, prompting immediate re‑rating.
Market effects
May weigh on broader med‑device sector as peers face similar demand slowdown.
U.S. healthcare stocks could see modest pullback.
Limited to investors with exposure to Stryker and related med‑device equities.
Counterpoint
If the market overreacts, the stock could rebound on its strong cash flow and dividend track record.
Key entities
- companyStryker Corp.
Medical device maker (NYSE:SYK).
- analystStifel
Equity research firm that cut SYK price target.
